FMO3 Protein (Transcript Variant 1) (Myc-DYKDDDDK Tag)

Catalog No. ABIN2721249

This Recombinant FMO3 protein is produced in HEK-293 Cells.

Quick Overview for FMO3 Protein (Transcript Variant 1) (Myc-DYKDDDDK Tag) (ABIN2721249)

Target: FMO3 (Flavin Containing Monooxygenase 3 (FMO3))

Protein Type: Recombinant

Origin: Human

Source: HEK-293 Cells

Application: Antibody Production (AbP), Standard (STD)

Purity: > 80 % as determined by SDS-PAGE and Coomassie blue staining

Product Details

Protein Characteristics: Transcript Variant 1

Purification tag / Conjugate: This FMO3 protein is labelled with Myc-DYKDDDDK Tag.

Characteristics:

• Recombinant human FMO3 (transcript variant 1) protein expressed in HEK293 cells.
• Produced with end-sequenced ORF clone

Application Details

Application Notes: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Comment:

The tag is located at the C-terminal.

Restrictions: For Research Use only

Handling

Concentration: 50 μg/mL

Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.

Storage: -80 °C

Storage Comment: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Target Details

Target: FMO3 (Flavin Containing Monooxygenase 3 (FMO3))

Alternative Name: Fmo3

Background: Flavin-containing monooxygenases (FMO) are an important class of drug-metabolizing enzymes that catalyze the NADPH-dependent oxygenation of various nitrogen-,sulfur-, and phosphorous-containing xenobiotics such as therapeutic drugs, dietary compounds, pesticides, and other foreign compounds. The human FMO gene family is composed of 5 genes and multiple pseudogenes. FMO members have distinct developmental- and tissue-specific expression patterns. The expression of this FMO3 gene, the major FMO expressed in adult liver, can vary up to 20-fold between individuals. This inter-individual variation in FMO3 expression levels is likely to have significant effects on the rate at which xenobiotics are metabolised and, therefore, is of considerable interest to the pharmaceutical industry. This transmembrane protein localizes to the endoplasmic reticulum of many tissues. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. Mutations in this gene cause the disorder trimethylaminuria (TMAu) which is characterized by the accumulation and excretion of unmetabolized trimethylamine and a distinctive body odor. In healthy individuals, trimethylamine is primarily converted to the non odorous trimethylamine N-oxide.[provided by RefSeq, Jan 2016].

Molecular Weight: 59.9 kDa

NCBI Accession: NP_008825